SEC 13F Intelligence

Managers / Q3 2023 · view latest →

Birchview Capital, LP

CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826

Reported Value
$117M
Q3 2023
Positions
52
Filings on Record
39
2019–present window
Filed
Nov 14, 2023
original filing

Summary

Birchview Capital, LP reported $117M in U.S.-listed holdings across 52 positions for Q3 2023.

The portfolio is heavily concentrated: BMY alone accounts for 35.4% of reported value.

Compared with Q2 2023, the fund opened 0 new positions and exited 3.

Portfolio Metrics

Turnover
+5.1%
vs prior filed quarter
Top-10 Concentration
+75.2%
share of reported value
Largest Position
+35.4%
Bristol Myers Squibb

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $160MQ2 ’19: $164MQ3 ’19: $150MQ4 ’19: $138MQ4 ’19Q1 ’20: $113MQ2 ’20: $165MQ3 ’20: $150MQ4 ’20: $174MQ4 ’20Q1 ’21: $168MQ2 ’21: $167MQ3 ’21: $147MQ4 ’21: $155MQ4 ’21Q1 ’22: $139MQ2 ’22: $137MQ3 ’22: $142MQ1 ’23: $127,725Q1 ’23Q3 ’23: $117MQ4 ’23: $128MQ1 ’24: $122MQ2 ’24: $108MQ2 ’24Q3 ’24: $115MQ4 ’24: $123MQ1 ’25: $115MQ2 ’25: $101MQ2 ’25Q3 ’25: $132MQ4 ’25: $171MQ1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 81.7%Other: 18.3%
  • Common Stock · 81.7% · $96M
  • Other · 18.3% · $21M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
AXGNAXOGEN INCADDED+133.0K173.0K+$499,800$865,000
GTHXEURG1 THERAPEUTICS INCADDED+80.0K120.0K+$73,200$172,800
GOSSGOSSAMER BIO INCADDED+110.0K209.1K+$55,222$174,128
SILKUSDSILK ROAD MEDICAL INCADDED+21.3K41.3K−$30,803$618,997
TVTXTRAVERE THERAPEUTICS INCADDED+42.0K82.0K+$118,680$733,080
SOLENO THERAPEUTICS INCSOLD OUT−245.1K0−$1M$0
OPHTEURIVERIC BIO INCSOLD OUT−25.0K0−$983,500$0
CHINOOK THERAPEUTICS INCSOLD OUT−15.0K0−$576,300$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2023

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BMYBRISTOL-MYERS SQUIBB COhistory →COM35.38%$42M716.3K
2NBIXNEUROCRINE BIOSCIENCES INChistory →COM7.40%$9M77.2K
3BIODESIX INCCOM7.08%$8M5.04M
4PROTHENA CORP PLCSHS6.96%$8M169.6K
5ACADACADIA PHARMACEUTICALS INChistory →COM4.26%$5M240.4K
6QDEL*QUIDELORTHO CORPhistory →COM4.05%$5M65.2K
7OVVOVINTIV INChistory →COM3.41%$4M84.2K
8IMGNEURIMMUNOGEN INChistory →COM2.57%$3M190.0K
9UTHUNITED THERAPEUTICS CORPhistory →COM2.11%$2M11.0K
10ELUTELUTIA INChistory →COM2.01%$2M1.66M
11HROWHARROW HEALTH INChistory →COM1.83%$2M150.0K
12PHRPHREESIA INChistory →COM1.31%$2M82.7K
13ALKERMES PLCSHS1.19%$1M50.0K
14BLUEBIRD BIO INCCOM1.18%$1M455.2K
15HTDCORCEPT THERAPEUTICS INChistory →COM1.16%$1M50.0K
16MASI*MASIMO CORPhistory →COM1.14%$1M15.3K
17FHTXFOGHORN THERAPEUTICS INChistory →COM1.13%$1M264.8K
18ACCELERATE DIAGNOSTICS INCCOM1.10%$1M225.2K
19INBXUSDINHIBRX INChistory →COM1.10%$1M70.4K
20ETRNUSDEQUITRANS MIDSTREAM CORPORATIOhistory →COM1.06%$1M133.1K
21ATECALPHATEC HOLDINGS INCCOM0.88%$1M80.0K
22VTYXUSDVENTYX BIOSCIENCES INCCOM0.78%$916,87226.4K
23PXDEURPIONEER NATURAL RESOURCES COCOM0.74%$872,2903.8K
24TXG10X GENOMICS INCCL A COM0.74%$866,25021.0K
25AXGNAXOGEN INCCOM0.74%$865,000173.0K
26KPTIEURKARYOPHARM THERAPEUTICS INCCOM0.65%$766,255571.8K
27CYTKCYTOKINETICS INCCOM0.63%$736,50025.0K
28TVTXTRAVERE THERAPEUTICS INCCOM0.62%$733,08082.0K
29DCGODOCGO INCCOM0.59%$692,900130.0K
30APLSUSDAPELLIS PHARMACEUTICALS INCCOM0.58%$684,72018.0K
31PTGXPROTAGONIST THERAPEUTICS INCCOM0.54%$633,84038.0K
32SILKUSDSILK ROAD MEDICAL INCCOM0.53%$618,99741.3K
33PGNYPROGYNY INCCOM0.52%$612,36018.0K
34KINIKSA PHARMACEUTICALS LTDCOM0.44%$521,10030.0K
354XC1KALVISTA PHARMACEUTICALS INCCOM0.33%$385,20040.0K
36HALOHALOZYME THERAPEUTICS INCCOM0.33%$382,00010.0K
37XENEXENON PHARMACEUTICALS INCCOM0.29%$341,60010.0K
38AM6AMICUS THERAPEUTICS INCCOM0.29%$340,48028.0K
39STOKSTOKE THERAPEUTICS INCCOM0.29%$334,90085.0K
40SRPTSAREPTA THERAPEUTICS INCCOM0.26%$303,0502.5K
41ARVNARVINAS INCCOM0.25%$294,60015.0K
42XNCRXENCOR INCCOM0.21%$247,84512.3K
43TSVT*2SEVENTY BIO INCCOM0.20%$234,54559.8K
44CGEMCULLINAN ONCOLOGY INCCOM0.19%$227,28225.1K
45KROSKEROS THERAPEUTICS INCCOM0.19%$223,1607.0K
46BIODESIX INC COM RSTCOM0.18%$211,765153.7K
47GOSSGOSSAMER BIO INCCOM0.15%$174,128209.1K
48GTHXEURG1 THERAPEUTICS INCCOM0.15%$172,800120.0K
49INFLARX NVCOM0.13%$149,00050.0K
50BCRXBIOCRYST PHARMACEUTICALS INCCOM0.12%$141,60020.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M73May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$171M68Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$132M69Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M71Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$115M68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$123M68Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$115M62Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$108M61Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$122M60May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M59Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$117M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review54Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$127,72555May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review57Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$142M60Nov 28, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$137M64Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$139M63May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$147M64Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$167M62Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$168M54May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$174M48Feb 9, 202113F-HRchanges · EDGAR ↗
Q3 2020$150M50Nov 12, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$165M51Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$113M46May 12, 202013F-HRchanges · EDGAR ↗
Q4 2019$138M52Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$150M50Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$164M54Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$160M54May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M52Feb 6, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.